• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Changes in demographics, treatment and outcomes in a  consecutive cohort who underwent transcatheter aortic valve implantation between 2005 and 2020
CONCLUSION: Over our 15 years' experience, patient age remained unchanged but the patient risk profile became more favourable. Simplification of the TAVI procedure occurred in parallel with major improvement in outcomes and survival. Bleeding/vascular complications and the need for pacemaker implantation remain the Achilles' heel of TAVI.PMID:35212972 | DOI:10.1007/s12471-022-01662-2
Source: Netherlands Heart Journal - February 25, 2022 Category: Cardiology Authors: M J A G De Ronde-Tillmans R M Nuis J A Goudzwaard P A Cummins T W Hokken M P H Van Wiechen J F W Ooms J Daemen N M D A Van Mieghem F U S Mattace-Raso M J Lenzen P P T de Jaegere Source Type: research

Major threats to early safety after transcatheter aortic valve implantation in a  contemporary cohort of real-world patients
CONCLUSION: A variety of underlying mechanisms and causes form a wide spectrum of major threats affecting early safety in 11.7% of patients undergoing TAVI in a contemporary cohort of real-world patients.PMID:34724147 | DOI:10.1007/s12471-021-01638-8
Source: Netherlands Heart Journal - November 1, 2021 Category: Cardiology Authors: D J van Ginkel J Brouwer N D van Hemert A O Kraaijeveld B J W M Rensing M J Swaans L Timmers M Voskuil P R Stella J M Ten Berg Source Type: research

Antithrombotic therapy in high-risk patients  after percutaneous coronary intervention; study design, cohort profile and incidence of adverse events
CONCLUSION: The high risk for both bleeding and ischaemic events in this cohort of patients with multiple clinical risk factors illustrates the challenges that the cardiologist faces to make a balanced decision on the optimal treatment strategy. This cohort will serve to answer several future research questions about the optimal management of these patients on dual/triple antithrombotic therapy, and the possible value of a wide range of laboratory tests to guide these decisions.PMID:34468944 | DOI:10.1007/s12471-021-01606-2
Source: Netherlands Heart Journal - September 1, 2021 Category: Cardiology Authors: R H Olie P E J van der Meijden M J A Vries L Veenstra A W J van 't Hof J M Ten Berg Y M C Henskens H Ten Cate Source Type: research

Impact of different anticoagulation management strategies on outcomes in atrial fibrillation: Dutch and Belgian results from the GARFIELD-AF registry.
CONCLUSIONS: In GARFIELD-AF, despite similar characteristics, patients on anticoagulants were treated differently in NL and BE. Although the rate of major bleeding was 33% higher in NL, variations in bleeding, mortality and TE rates were not statistically significant. PMID: 32886853 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - September 3, 2020 Category: Hematology Authors: Seelig J, Hemels MEW, Xhaët O, Bongaerts MCM, de Wolf A, Groenemeijer BE, Heyse A, Hoogslag P, Voet J, Herrman JR, Vervoort G, Hermans W, Wollaert B, Boersma LVA, Hermans K, Lucassen A, Verstraete S, Adriaansen HJ, Mairesse GH, Terpstra WF, Faes D, Piete Tags: J Thromb Haemost Source Type: research

The role of long-term mechanical circulatory support in patients with advanced heart failure.
Abstract In patients with end-stage heart failure, advanced therapies such as heart transplantation and long-term mechanical circulatory support (MCS) with a left ventricular assist device (LVAD) have to be considered. LVADs can be implanted as a bridge to transplantation or as an alternative to heart transplantation: destination therapy. In the Netherlands, long-term LVAD therapy is gaining importance as a result of increased prevalence of heart failure together with a low number of heart transplantations due to shortage of donor hearts. As a result, the difference between bridge to transplantation and desti...
Source: Netherlands Heart Journal - July 31, 2020 Category: Cardiology Authors: Felix SEA, de Jonge N, Caliskan K, Birim O, Damman K, Kuijpers M, Tops LF, Palmen M, Ramjankhan FZ Tags: Neth Heart J Source Type: research

Antithrombotic management of patients with atrial fibrillation-Dutch anticoagulant initiatives anno 2020.
Abstract In recent years, as more and more experience has been gained with prescribing direct oral anticoagulants (DOACs), new research initiatives have emerged in the Netherlands to improve the safety and appropriateness of DOAC treatment for stroke prevention in patients with atrial fibrillation (AF). These initiatives address several contemporary unresolved issues, such as inappropriate dosing, non-adherence and the long-term management of DOAC treatment. Dutch initiatives have also contributed to the development and improvement of risk prediction models. Although fewer bleeding complications (notably intracran...
Source: Netherlands Heart Journal - July 31, 2020 Category: Cardiology Authors: Chu G, Seelig J, Trinks-Roerdink EM, Geersing GJ, Rutten FH, de Groot JR, Huisman MV, Hemels MEW Tags: Neth Heart J Source Type: research

Outcome of mechanical circulatory support at the University Medical Centre Utrecht.
CONCLUSION: Not only short-term results but also 5‑year survival after cf-LVAD support demonstrate that MCS is a promising therapy as an extended bridge to heart transplantation. However, the incidence of several major complications still has to be addressed. PMID: 32096095 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - February 23, 2020 Category: Cardiology Authors: Felix SEA, Ramjankhan FZ, Buijsrogge MP, Jacob KA, Asselbergs FW, Oerlemans MIF, Kirkels JH, van Laake LW, Oppelaar AMC, Suyker WJL, de Jonge N Tags: Neth Heart J Source Type: research

Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation.
Conclusion: DOAC discontinuation rates varied significantly and appeared related to drug-specific side effects, patient-initiated discontinuation, and bleeding. We observed longer-term administration of apixaban, suggesting that this drug is better tolerated than dabigatran or rivaroxaban. PMID: 32011180 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 5, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Management and outcomes of real-world use of non-vitamin-K oral anticoagulants (NOACs) in patients with atrial fibrillation: experience of a  dedicated NOAC clinic.
CONCLUSIONS: We observed low rates of bleeding and adverse drug reactions. However, rates of mortality and discontinuation were relatively high. These results could possibly be explained by the real-world nature of the data including higher-risk patients. PMID: 31773474 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - November 25, 2019 Category: Cardiology Authors: de Veer AJWM, Bennaghmouch N, Wijffels MCEF, Ten Berg JM Tags: Neth Heart J Source Type: research

Safety and efficacy of a self-expanding versus a balloon-expandable bioprosthesis for transcatheter aortic valve replacement in patients with symptomatic severe aortic stenosis: a randomised non-inferiority trial
Publication date: Available online 27 September 2019Source: The LancetAuthor(s): Jonas Lanz, Won-Keun Kim, Thomas Walther, Christof Burgdorf, Helge Möllmann, Axel Linke, Simon Redwood, Christian Thilo, Michael Hilker, Michael Joner, Holger Thiele, Lars Conzelmann, Lenard Conradi, Sebastian Kerber, Gerhard Schymik, Bernard Prendergast, Oliver Husser, Stefan Stortecky, Dik Heg, Peter JüniSummaryBackgroundTranscatheter aortic valve replacement (TAVR) is the preferred treatment option for older patients with symptomatic severe aortic stenosis. Differences in the properties of available TAVR systems can affect clinical outcom...
Source: The Lancet - September 28, 2019 Category: General Medicine Source Type: research

Design and rationale of ischaemia-driven complete revascularisation versus usual care in patients with non-ST-elevation myocardial infarction and multivessel coronary disease: the South Limburg Myocardial Infarction (SLIM) trial.
CONCLUSION: The SLIM trial aims to provide evidence whether FFR-guided complete revascularisation by PCI is superior to usual care with respect to clinical outcomes (major adverse cardiovascular events) in non-STEMI patients with MVD. PMID: 31531823 [PubMed - as supplied by publisher]
Source: Netherlands Heart Journal - September 16, 2019 Category: Cardiology Authors: Pustjens TFS, Streukens B, Vainer J, Gho B, Ruiters AW, Stein M, Ilhan M, Veenstra L, Theunissen R, Bekkers SCAM, Van't Hof AWJ, Rasoul S Tags: Neth Heart J Source Type: research

Pages: 1  2  3  4